The cost of major comorbidity in people with diabetes mellitus

CMAJ. Canadian Medical Association Journal

Volumn 168, Issue 13, 2003, Pages 1661-1667

  Simpson, Scot H ^a   Corabian, Paula ^b   Jacobs, Philip ^a,c   Johnson, Jeffrey A ^a,c  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b Alta Her Found for Med Research   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; COST CONTROL; DIABETES MELLITUS; ECONOMIC ASPECT; EYE DISEASE; FEMALE; HEALTH CARE COST; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE;

EID: 0038045161     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Diabetes in Canada: national statistics and opportunities for improved surveillance, prevention, and control. Ottawa: Health Canada, 1999. Cat no H49-121/1999.
2. Morrish NJ, Wang S-L, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001;44(Suppl 2):S14-S21.
3. Tan MH, MacLean DR. Epidemiology of diabetes mellitus in Canada. Clin Invest Med 1995;18:240-6.
4. Wingard DL, Barrett-Connor E, Criqui MH, Suarez L. Clustering of heart disease risk factors in diabetic compared to nondiabetic adults. Am J Epidemiol 1983;117:19-26.
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
6. Gatling W, Tufail S, Mullee MA, Westacott TA, Hill RD. Mortality rates in diabetic patients from a community-based population compared to local age/sex matched controls. Diabet Med 1997;14:316-20.
7. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998;21:1138-45.
8. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
9. Jude EB, Oyibo SO, Chalmers N, Boulton AJM. Peripheral arterial disease in diabetic and nondiabetic patients. Diabetes Care 2001;24:1433-7.
10. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care 1998;21:296-309.
11. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997;20:1396-402.
12. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics 1999;16:285-95.
13. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-80.
14. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998;21:1122-8.
15. Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada, 1998. Diabetes Care 2002;25:1303-7.
16. Downey W, Beck P, McNutt M, Stang M, Osei W, Nichol J. Health data-bases in Saskatchewan. In: Strom B, editor. Pharmacoepidemiology. Chinchester: Wiley; 2000. p. 325-45.
17. World Health Organization manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, 9th.rev. Geneva: World Health Organization; 1977.
18. Blanchard JF, Ludwig S, Wajda A, Dean H, Anderson K, Kendall O, et al. Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes Care 1996;19:807-11.
19. Hux JE, Ivis F, Flintoff V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-6.
20. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002;40:611-22.
21. Johnson JA, Connolly MA, Jacobs P, Montgomery M, Brown N, Zuberbuhler P. Costs of care for individuals with cystic fibrosis in Alberta: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999;19:1159-66.
22. Hu TW, Jerrell J. Cost-effectiveness of alternative approaches in treating severely mentally ill in California. Schizophr Bull 1991;17:461-8.
23. Johnson JA, Simpson SH, Jacobs P, Downey W, Beck P, Osei W. Cost of health care for people with diabetes mellitus in Saskatchewan 1991 to 1996. Edmonton: Institute of Health Economics, 2002. Working paper 02-02.
24. Report of the Saskatchewan Advisory Committee on Diabetes. Diabetes 2000: recommendations for a strategy on diabetes prevention and control in Saskatchewan. Regina: Saskatchewan Health, 2000.
25. Huse DM, Oster G, Killen AR, Lacy MJ, Colditz GA. The economic cost of non-insulin-dependent diabetes mellitus. JAMA 1989;262:2708-13.
26. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care 2002;25:482-6.
27. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ 1998;159(Suppl 8):S1-29.
28. Implications of the diabetes control and complications trial. American Diabetes Association. Diabetes Care 2002;25(Suppl 1):S25-7.
29. Implications of the United Kingdom prospective diabetes study. American Diabetes Association. Diabetes Care 2002;25(Suppl 1):S28-32.
30. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
31. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9.
32. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-9.
33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998;352:837-53.
34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study Group. Lancet 1998;352:854-65.
35. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. BMJ 1982;285:685-8.
36. Parving HH, Rossing P, Hommel E, Schmidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995;26:99-107.
37. Marre M, Chatellier G, Leblanc H, Guyenne TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988;297:1092-5.
38. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
39. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
40. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among individuals with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
41. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 2002;346:393-403.
42. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-7.